ITGR Earnings Date: Feb 18, 2027 (Estimated) — Integer Holdings Corporation
NYSE · Healthcare · Medical Devices
Updated
When is ITGR's next earnings date?
Integer Holdings Corporation (ITGR) is expected to report Q4 2026 earnings on Thursday, February 18, 2027 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.78 on revenue of $465.6M.
How did ITGR do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Integer Holdings Corporation posted EPS of $1.34 versus the $1.68 estimate, a miss of 20.2%. Revenue was $449.7M against a $456.9M estimate. The stock's 1-day post-earnings move was -0.0%.
How much does ITGR stock move after earnings?
ITGR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About Integer Holdings Corporation
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
🤖 AI Earnings Analysis
Integer’s Q3 results are concerning: the medical-device supplier missed EPS by $0.34 and revenue by $7M, with sales down 3.8% year over year to $450M. EPS fell 25% to $1.34, signaling broad weakness rather than a one-off miss.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 1.68 | 1.34 | -20.24% | $449.7M | ❌ Miss | -0.02% | — | — |
| 2026-08-03 | Q2 2026 | 1.38 | 1.60 | +15.94% | $464.1M | ✅ Beat | +2.67% | +3.35% | +3.33% |
| 2026-04-30 | Q1 2026 | 1.19 | 1.20 | +0.84% | $439.6M | ✅ Beat | +5.78% | +3.13% | +6.82% |
| 2026-02-19 | Q4 2025 | 1.70 | 1.76 | +3.53% | $470.1M | ✅ Beat | -4.02% | +0.02% | -2.45% |
| 2025-10-23 | Q3 2025 | 1.68 | 1.79 | +6.55% | $467.7M | ✅ Beat | -32.28% | -40.15% | -37.56% |
| 2025-04-24 | Q1 2025 | 1.24 | 1.31 | +5.65% | $437.4M | ✅ Beat | +0.79% | +4.81% | -1.95% |
| 2025-02-20 | Q4 2024 | 1.46 | 1.43 | -2.05% | $449.5M | ❌ Miss | -5.58% | -11.83% | -18.80% |
| 2024-10-24 | Q3 2024 | 1.36 | 1.43 | +5.15% | $431.4M | ✅ Beat | +0.18% | +2.69% | +7.39% |
Showing last 8 quarters.